Browse SERPINE1

Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00079 Serpin (serine protease inhibitor)
Function

Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:8481516, PubMed:9207454, PubMed:17912461). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084).

> Gene Ontology
 
Biological Process GO:0001300 chronological cell aging
GO:0001525 angiogenesis
GO:0001819 positive regulation of cytokine production
GO:0001952 regulation of cell-matrix adhesion
GO:0001953 negative regulation of cell-matrix adhesion
GO:0002237 response to molecule of bacterial origin
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002538 arachidonic acid metabolite production involved in inflammatory response
GO:0002540 leukotriene production involved in inflammatory response
GO:0002548 monocyte chemotaxis
GO:0002576 platelet degranulation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0007160 cell-matrix adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007568 aging
GO:0007569 cell aging
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0007623 circadian rhythm
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0010466 negative regulation of peptidase activity
GO:0010469 regulation of receptor activity
GO:0010755 regulation of plasminogen activation
GO:0010757 negative regulation of plasminogen activation
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0010951 negative regulation of endopeptidase activity
GO:0010955 negative regulation of protein processing
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014912 negative regulation of smooth muscle cell migration
GO:0016485 protein processing
GO:0016525 negative regulation of angiogenesis
GO:0030100 regulation of endocytosis
GO:0030193 regulation of blood coagulation
GO:0030194 positive regulation of blood coagulation
GO:0030195 negative regulation of blood coagulation
GO:0030198 extracellular matrix organization
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0031589 cell-substrate adhesion
GO:0031638 zymogen activation
GO:0031639 plasminogen activation
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032637 interleukin-8 production
GO:0032677 regulation of interleukin-8 production
GO:0032757 positive regulation of interleukin-8 production
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033629 negative regulation of cell adhesion mediated by integrin
GO:0035490 regulation of leukotriene production involved in inflammatory response
GO:0035491 positive regulation of leukotriene production involved in inflammatory response
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0042730 fibrinolysis
GO:0042742 defense response to bacterium
GO:0043062 extracellular structure organization
GO:0045055 regulated exocytosis
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045807 positive regulation of endocytosis
GO:0045861 negative regulation of proteolysis
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048260 positive regulation of receptor-mediated endocytosis
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050819 negative regulation of coagulation
GO:0050820 positive regulation of coagulation
GO:0050829 defense response to Gram-negative bacterium
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0051917 regulation of fibrinolysis
GO:0051918 negative regulation of fibrinolysis
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060055 angiogenesis involved in wound healing
GO:0060326 cell chemotaxis
GO:0060627 regulation of vesicle-mediated transport
GO:0061041 regulation of wound healing
GO:0061042 vascular wound healing
GO:0061043 regulation of vascular wound healing
GO:0061044 negative regulation of vascular wound healing
GO:0061045 negative regulation of wound healing
GO:0061302 smooth muscle cell-matrix adhesion
GO:0070613 regulation of protein processing
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0072577 endothelial cell apoptotic process
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090303 positive regulation of wound healing
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097529 myeloid leukocyte migration
GO:0098542 defense response to other organism
GO:1900046 regulation of hemostasis
GO:1900047 negative regulation of hemostasis
GO:1900048 positive regulation of hemostasis
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:2000097 regulation of smooth muscle cell-matrix adhesion
GO:2000098 negative regulation of smooth muscle cell-matrix adhesion
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0002020 protease binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04066 HIF-1 signaling pathway
hsa04115 p53 signaling pathway
hsa04390 Hippo signaling pathway
hsa04610 Complement and coagulation cascades
Reactome R-HSA-1368108: BMAL1
R-HSA-400253: Circadian Clock
R-HSA-75205: Dissolution of Fibrin Clot
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SERPINE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SERPINE1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SERPINE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0890.0478
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7930.426
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5560.696
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.3260.0554
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7540.496
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.780.818
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0630.93
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.490.768
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4590.795
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7380.39
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.7670.372
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2070.373
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SERPINE1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SERPINE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SERPINE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SERPINE1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SERPINE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SERPINE1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SERPINE1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSERPINE1
Nameserpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Aliases plasminogen activator inhibitor, type I; PLANH1; PAI1; serine (or cysteine) proteinase inhibitor, clade E (n ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SERPINE1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SERPINE1.
ID Name Drug Type Targets #Targets
DB00009AlteplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00013UrokinaseBiotechLRP2, NID1, PLAT, PLAU, PLAUR, PLG, SERPINA5, SERPINB2, SERPINE1, ......10
DB00015ReteplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00029AnistreplaseBiotechFGA, PLAUR, PLG, SERPINE14
DB00031TenecteplaseBiotechANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......11
DB00055Drotrecogin alfaBiotechCP, F2, F5, F8, GGCX, PF4, PROCR, PROS1, SERPINA5, SERPINB6, SERPI ......12
DB00197TroglitazoneSmall MoleculeACSL4, ESRRA, ESRRG, GSTP1, PPARA, PPARD, PPARG, SERPINE1, SLC29A19
DB05254FibrinolysinBiotechPLAU, SERPINE12
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141